UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 814

Sortiert nach

Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial

Lancet neurology, 2014-10, Vol.13 (10), p.977-986

2014

Volltextzugriff (PDF)

A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis

The New England journal of medicine, 2006-03, Vol.354 (9), p.899-910

2006

Volltextzugriff (PDF)

Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study

Lancet neurology, 2009-03, Vol.8 (3), p.254-260

2009

Volltextzugriff (PDF)

Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria"

Annals of neurology, 2005-12, Vol.58 (6), p.840-846

2005

Volltextzugriff (PDF)

A Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis

The New England journal of medicine, 2003-01, Vol.348 (1), p.15-23

2003

Volltextzugriff (PDF)

Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring

Lancet neurology, 2007-05, Vol.6 (5), p.431-441

2007

Volltextzugriff (PDF)

Assessment of JC virus DNA in blood and urine from natalizumab-treated patients

Annals of neurology, 2010-09, Vol.68 (3), p.304-310

2010

Volltextzugriff (PDF)

Teriflunomide effect on immune response to influenza vaccine in patients with multiple sclerosis

Neurology, 2013-08, Vol.81 (6), p.552

2013

Volltextzugriff (PDF)

Oral versus intravenous steroids for treatment of relapses in multiple sclerosis

Cochrane database of systematic reviews, 2012-12, Vol.12, p.CD006921

2012

Volltextzugriff (PDF)

Evidence Report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology

Neurology, 2010-05, Vol.74 (18), p.1463

2010

Volltextzugriff (PDF)

Emerging therapies in relapsing-remitting multiple sclerosis

Reviews on recent clinical trials, 2010-09, Vol.5 (3), p.179

2010

Volltextzugriff (PDF)

Established disease-modifying treatments in relapsing-remitting multiple sclerosis

Current opinion in neurology, 2015-06, Vol.28 (3), p.220-229

2015

Volltextzugriff (PDF)

The efficacy of teriflunomide in patients who received prior disease-modifying treatments: Subgroup analyses of the teriflunomide phase 3 TEMSO and TOWER studies

Multiple sclerosis, 2018-04, Vol.24 (4), p.535-539

2018

Volltextzugriff (PDF)

Safety, Tolerability, and Efficacy of Oral Therapies for Relapsing-Remitting Multiple Sclerosis

CNS drugs, 2013-08, Vol.27 (8), p.591-609

2013

Volltextzugriff (PDF)

Long-term follow-up of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5 years

Multiple sclerosis, 2012-09, Vol.18 (9), p.1278-1289

2012

Volltextzugriff (PDF)

Multiple sclerosis in 2014. Progress in MS--classification, mechanisms and treatment

Nature reviews. Neurology, 2015-02, Vol.11 (2), p.76

2015

Volltextzugriff (PDF)

The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL

Journal of neurology, 2009-03, Vol.256 (3), p.405-415

2009

Volltextzugriff (PDF)

Teriflunomide for the treatment of multiple sclerosis

Seminars in neurology, 2013-02, Vol.33 (1), p.45

2013

Volltextzugriff (PDF)

Teriflunomide in the treatment of multiple sclerosis: current evidence and future prospects

Therapeutic Advances in Neurological Disorders, 2014-09, Vol.7 (5), p.239-252

2014

Volltextzugriff (PDF)

Adherence to Multiple Sclerosis Disease-Modifying Therapies in Ontario is Low

Canadian journal of neurological sciences, 2011-05, Vol.38 (3), p.429-433

2011

Volltextzugriff (PDF)

Severity of chronic pain and its relationship to quality of life in multiple sclerosis

Multiple sclerosis, 2005-06, Vol.11 (3), p.322-327

2005

Volltextzugriff (PDF)

Novel and imminently emerging treatments in relapsing-remitting multiple sclerosis

Current opinion in neurology, 2015-06, Vol.28 (3), p.230-236

2015

Volltextzugriff (PDF)

Sustained improvement in Expanded Disability Status Scale as a new efficacy measure of neurological change in multiple sclerosis: treatment effects with natalizumab in patients with relapsing multiple sclerosis

Multiple sclerosis, 2011-08, Vol.17 (8), p.970-979

2011

Volltextzugriff (PDF)

1 – 25 von 814

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(745)
Mit Volltextzugriff
(723)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(569)
Life Sciences & Biomedicine
(507)
Humans
(399)
Male
(261)
Female
(224)
Biological And Medical Sciences
(176)
Middle Aged
(172)
Medical Sciences
(158)
Aged
(139)
Adult
(130)
Cardiovascular System & Cardiology
(123)
Animals
(117)
Cardiac & Cardiovascular Systems
(108)
Neurosciences & Neurology
(89)
Clinical Neurology
(76)
Treatment Outcome
(74)
Heart Failure
(73)
General & Internal Medicine
(59)
Neurology
(56)
Adolescent
(49)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(8)

Menü

Weitere Dienste

Einstellungen

Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial

A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis

Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study

Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria"

A Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis

Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring

Assessment of JC virus DNA in blood and urine from natalizumab-treated patients

Defining the clinical course of multiple sclerosis: the 2013 revisions

Teriflunomide effect on immune response to influenza vaccine in patients with multiple sclerosis

Oral versus intravenous steroids for treatment of relapses in multiple sclerosis

Evidence Report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology

Emerging therapies in relapsing-remitting multiple sclerosis

Established disease-modifying treatments in relapsing-remitting multiple sclerosis

The efficacy of teriflunomide in patients who received prior disease-modifying treatments: Subgroup analyses of the teriflunomide phase 3 TEMSO and TOWER studies

Safety, Tolerability, and Efficacy of Oral Therapies for Relapsing-Remitting Multiple Sclerosis

Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring

Long-term follow-up of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5 years

Multiple sclerosis in 2014. Progress in MS--classification, mechanisms and treatment

The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL

Teriflunomide for the treatment of multiple sclerosis

Teriflunomide in the treatment of multiple sclerosis: current evidence and future prospects

Adherence to Multiple Sclerosis Disease-Modifying Therapies in Ontario is Low

Severity of chronic pain and its relationship to quality of life in multiple sclerosis

Novel and imminently emerging treatments in relapsing-remitting multiple sclerosis

Sustained improvement in Expanded Disability Status Scale as a new efficacy measure of neurological change in multiple sclerosis: treatment effects with natalizumab in patients with relapsing multiple sclerosis

Suchergebnisse filtern